Estela Rodriguez: FDA Declines to Approve Summit Therapeutics Ivonescimab For Lung Cancer
Estela Rodriguez/X

Estela Rodriguez: FDA Declines to Approve Summit Therapeutics Ivonescimab For Lung Cancer

Estela Rodriguez, Associate Director of Community Outreach in Thoracic Oncology at the University of Miami’s Sylvester Comprehensive Cancer Center, shared on X:

“It’s been a weird week. Planes grounded, Outlook down, and now FDA declines to approve Summit Therapeutics ivonescimab for EGFR-mutant lung cancer after osimertinib resistance (HARMONi trial).

Despite a meaningful PFS benefit, lack of demonstrated OS benefit was the deciding factor – a challenging standard, particularly when other cancer drugs have been approved with similar PFS/OS discrepancies in this space.”

You can also read: FDA Declines Ivonescimab Plus Chemotherapy Approval in EGFR-Mutated NSCLC Following HARMONi Results.

Estela Rodriguez